Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
about
Analysis of the small RNA transcriptional response in multidrug-resistant Staphylococcus aureus after antimicrobial exposureReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsMechanisms of vancomycin resistance in Staphylococcus aureusRelationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infectionsEvolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKRWhole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureusSynergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelJANE: efficient mapping of prokaryotic ESTs and variable length sequence reads on related template genomes.Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patientsTwo novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection.Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.Complete genome sequence of Staphylococcus aureus strain JKD6008, an ST239 clone of methicillin-resistant Staphylococcus aureus with intermediate-level vancomycin resistance.Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysisAn approach to identifying drug resistance associated mutations in bacterial strainsGuidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the EuReduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.Convergent adaptation in the dominant global hospital clone ST239 of methicillin-resistant Staphylococcus aureus.Early agr activation correlates with vancomycin treatment failure in multi-clonotype MRSA endovascular infections.A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'iGenetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates.Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureuSerine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureusHealth care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycinGeneration of ramoplanin-resistant Staphylococcus aureus.Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significanceTreatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Vancomycin: does it still have a role as an antistaphylococcal agent?Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureusComparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains.Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored by In Vivo Bioluminescent Imaging.Ideal microbiological and pharmacological characteristics of a quality antimicrobial agent: comparing original and generic molecules.Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus
P2860
Q24596120-7FE9D345-DB5A-4013-B2AF-08C27C2BE92AQ24646677-63CBACD3-36A9-4C0D-B557-6BC704D2641FQ26829312-4178D85B-EB0F-45CF-8759-B9277D71E35FQ27011138-0CE251FD-1041-43DE-B563-FAEE0610A35DQ28477900-5D4B74F9-ED4C-4CE5-B3C3-07C72B76EC50Q28478770-0312518D-E756-4032-BE69-1A4B1B390634Q28481497-4ABA70DE-243F-4CB1-9D83-09B813D4EA08Q30924146-0D910C53-06D1-4C99-B484-68FFB0CB7A1FQ33321447-2B76C68C-7C9D-4862-825B-EA03715F0B46Q33500363-ABD313B6-EFEC-4FAB-8E0E-1F0E6D6339D6Q33604815-E67886E4-205D-498F-B438-C1C9EAD9BFD8Q33613735-10130043-E7AA-405A-83B1-B94CF9AA33ACQ33826253-CF81A5C0-73E6-493B-B8D5-35F46BC81A29Q34058222-BDDEA7C4-A12A-4191-9CD5-A550C2CB1F8DQ34108614-1AD4045F-1B5A-4B3B-9529-B7C18CD119B7Q34192736-905747B3-678D-477C-BAE6-364296FE4854Q34405301-825149EC-8A77-4CCC-BE7F-E1DA1AAB0BA0Q34530052-5E1C05AB-6994-41E3-9A08-4C0BB143E40FQ34611253-2ACDAE91-1244-4626-916F-E992BA767629Q34998629-F049E753-47A0-426A-9FD7-E78E843508C3Q35172374-A9EA14B7-4AB0-4481-8137-C36BDCD43C67Q35432686-3803FF8A-F19D-4995-B6C6-4DAD4D5FE45DQ35549808-AF97E658-1095-499E-A5FF-EDF36601F14EQ35728976-35212E05-1E87-4CE9-BE0D-82040DB2B6FAQ36008997-0F07B8B5-06B8-455F-A728-7D0D653A65FBQ36098762-88B15657-E830-457E-9BA3-6C53B4309367Q36153912-C94E7A07-58C4-4236-A1C7-0B8DC936E618Q36452459-EC652C90-FD50-49B2-BC04-B20482FFB57CQ36680162-25F2A5D7-0AEA-4739-BDC1-3B889FFBEBFBQ36692468-A737DDF2-9DB9-44C4-85E9-0E9C0BD29803Q36758570-2C9D73EE-29D6-439C-ABAB-1729BF38744AQ36839712-703CD68D-F09C-44BA-A0B9-946C2E50D4C0Q36898180-1C2C34AE-4370-4945-AF88-FE38AB8FD19FQ36932920-78604786-8AF1-401E-9AD5-72D9746D2E48Q36964857-76FE5E15-C43D-43B8-9182-EF9EE6416301Q36969754-C40713D0-920A-49C8-B0E6-D94BE6D8BEACQ36972978-2CF6E6B7-1417-4224-8E68-DC5019DF767BQ37023281-EB0BFD77-95AF-46A1-BD47-3CCD65546F77Q37071315-C6752AD9-9B92-4D1E-8EC4-C95C7CD7B667Q37115797-496949AB-39A3-4006-B97A-58761B4B8595
P2860
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Isolates with low-level vancom ...... phylococcus aureus bacteremia.
@ast
Isolates with low-level vancom ...... phylococcus aureus bacteremia.
@en
type
label
Isolates with low-level vancom ...... phylococcus aureus bacteremia.
@ast
Isolates with low-level vancom ...... phylococcus aureus bacteremia.
@en
prefLabel
Isolates with low-level vancom ...... phylococcus aureus bacteremia.
@ast
Isolates with low-level vancom ...... phylococcus aureus bacteremia.
@en
P2093
P2860
P356
P1476
Isolates with low-level vancom ...... phylococcus aureus bacteremia.
@en
P2093
John K Davies
Paul D R Johnson
Peter B Ward
P2860
P304
P356
10.1128/AAC.00422-06
P407
P577
2006-09-01T00:00:00Z